We are holding steady to our fair value estimate and wide moat rating for Pfizer PFE following first-quarter results that largely matched our expectations. The company is tracking well to meet its ...

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Pfizer PFE reported fourth-quarter earnings ahead of our expectations, largely due to lower-than-expected research and development spending. However, we don’t expect this will continue, so there is no ...

Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. That kind of price decline doesn't happen by accident, which means you need to carefully ...

Durability, not yield, is the deciding factor.

Pfizer and China’s Innovent Biologics signed a global agreement worth up to $10.5 billion, including a $650 million upfront payment, to develop 12 oncology programs.